Implementation of CRP Point of Care Testing in Primary Care to Improve Antibiotic Targeting in Respiratory Illness (ICAT)
NCT ID: NCT03855215
Last Updated: 2022-04-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
2606 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-06-01
Study Completion Date
2021-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The proposed study will monitor and evaluate a quality improvement project - the introduction of commercially available lateral flow CRP tests with international regulatory approval, as a routine care service to improve the management of patients with acute respiratory infection (ARI) and reduce unnecessary antibiotic prescribing. No research staff will be present, and to minimise disruption and alteration of routine care, a waiver of written patient informed consent will be requested from the relevant ethical review boards, in accordance with the 2016 WHO/CIOMS International Guidance for Health-related Research Involving Humans8. Instead, patients in intervention clusters will be provided with information concerning how the test can assist healthcare workers in identifying when antibiotics are required, after which they will be free to refuse its use.
The test selected for use in the study is the Actim® CRP test from Medix Biochemica (Finland; ISO certification ISO13485:2016). The test is a simple lateral flow device that uses capillary blood, obtained through a finger/heel puncture. The test provides a semi-quantitative indication of whether CRP concentrations are \<10mg/L, between 10-40mg/L, between 40-80mg/L, or above 80mg/L, in under 5 minutes with minimal training requirements. The test has been approved by the European regulatory body (CE-marking) as well as in 13 other countries around the world (including Switzerland, Norway, Iceland, Israel and Thailand) and has been validated for accuracy in previous publications.9,10 Our own research group has also confirmed the tests' accuracy in both laboratory and field environments, including their thermos-stability in a tropical climate (see annex). Neither Medix Biochemica nor any of its distributors, have had involvement with the design of the evaluation and our group has no conflict of interest with respect to the choice of the test.
Main research question: Can point of care CRP tests introduced in routine primary healthcare reduce prescription of antibiotics for patients with acute respiratory infections, outside of the research context?
Brief description of the intervention: The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam (CHC details are described in the Location section below). Prior to introduction of the tests, an educational session will be provided for local healthcare workers in both intervention and control arms about the role of antibiotics and AMR. After randomization, further training will be provided for healthcare workers in the intervention CHCs as to the use of CRP testing to guide antibiotic prescribing decisions. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI (detailed in section 5.4). Educational materials will also be developed for patients and care-givers regarding the value of CRP testing.
Description of the population to be studied: This study will be conducted in the general population of Nam Dinh, a rural province in northern Vietnam. The test will be provided at CHCs and recommended for use in patients presenting with a chief complaint of ARI.
The test selected for use in the study is the Actim® CRP test from Medix Biochemica (Finland; ISO certification ISO13485:2016). The test is a simple lateral flow device that uses capillary blood, obtained through a finger/heel puncture. The test provides a semi-quantitative indication of whether CRP concentrations are \<10mg/L, between 10-40mg/L, between 40-80mg/L, or above 80mg/L, in under 5 minutes with minimal training requirements. The test has been approved by the European regulatory body (CE-marking) as well as in 13 other countries around the world (including Switzerland, Norway, Iceland, Israel and Thailand) and has been validated for accuracy in previous publications.9,10 Our own research group has also confirmed the tests' accuracy in both laboratory and field environments, including their thermos-stability in a tropical climate (see annex). Neither Medix Biochemica nor any of its distributors, have had involvement with the design of the evaluation and our group has no conflict of interest with respect to the choice of the test.
Main research question: Can point of care CRP tests introduced in routine primary healthcare reduce prescription of antibiotics for patients with acute respiratory infections, outside of the research context?
Brief description of the intervention: The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam (CHC details are described in the Location section below). Prior to introduction of the tests, an educational session will be provided for local healthcare workers in both intervention and control arms about the role of antibiotics and AMR. After randomization, further training will be provided for healthcare workers in the intervention CHCs as to the use of CRP testing to guide antibiotic prescribing decisions. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI (detailed in section 5.4). Educational materials will also be developed for patients and care-givers regarding the value of CRP testing.
Description of the population to be studied: This study will be conducted in the general population of Nam Dinh, a rural province in northern Vietnam. The test will be provided at CHCs and recommended for use in patients presenting with a chief complaint of ARI.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
C Reactive Protein (CRP) Intervention to Reduce Inappropriate Antibiotic Prescriptions in the Primary Healthcare Setting
NCT01918579
Acute Respiratory Infections
COMPLETED
NA
PCOT for Outpatients With Acute Respiratory Tract Infection at Risk of Severe Disease in Primary Healthcare
NCT07159230
Acute Respiratory Tract Infection
NOT_YET_RECRUITING
NA
C-reactive Protein (CRP)-Guided Management Algorithm for Adults With Acute Cough
NCT00221351
Cough
COMPLETED
NA
Point of Care Polymerase Chain Reaction (PCR) Diagnostics of Respiratory Tract Infections in General Practice
NCT06120153
Respiratory Tract Infections
ACTIVE_NOT_RECRUITING
NA
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
NCT00001477
Communicable Diseases
Opportunistic Infections
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
STUDY PROCEDURES
1. Screening and Recruitment - A list of potential CHCs will be compiled by province-level officials, and those meeting eligibility criteria will be invited to take part. CHCs will be randomly allocated to intervention or routine care arms using a computer-generated random allocation procedure.
If baseline variability in antibiotic prescribing practices is identified from reviewing retrospective routine records, high and low prescription centres will be stratified.
In the intervention CHCs, patients with ARIs will be provided leaflets with information about CRP testing, antibiotics and AMR. Healthcare workers will then decide whether to use a CRP test as part of routine care of patients with ARI. Patients' autonomy will be respected and as with any medical procedure this test can be declined. In the control CHCs patients will be provided with an information leaflet regarding the need for rational use of antibiotics in ARIs but with no mention of CRP testing.
2. Clinical assessment - All patients will have a medical history taken and will be examined as per normal practice. In the control arm, local guidelines and WHO IMCI recommendations will guide treatment. In the intervention arm, doctors can choose to use CRP test results in addition to existing guidelines.
3. General training and education - Healthcare worker training - Before the study sites (CHCs) are randomized, an overview of the study will be presented to all local healthcare workers and provide education about the role of antibiotics, antimicrobial resistance and identification of clinical signs of severity as well as good clinical practice (GCP) for research.
Patient education - Educational materials will be developed for patients and care-givers regarding antibiotic use and AMR. These will be available to patients presenting with ARIs in both arms, with additional information regarding the CRP tests added to the intervention group leaflets.
4. Intervention - CRP test - The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.
Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.
As the purpose of the study is to establish whether antibiotic prescription rates can be reduced by using CRP POC test results, the healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs below are recommended in the absence of warning signs of severity:
CRP level \< 10 mg/L: no antibiotics are recommended CRP level from 10mg/L to 40 mg/L: antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level \> 40 mg/L: antibiotics are recommended. Based on the previous clinical trial of CRP testing in ARI in Vietnam in similar CHCs, it's anticipated approximately 75% of patients to have CRP levels below 10mg/L, 20% between 10-40mg/L and 5% above 40 mg/L6.
Healthcare worker training - Additional training will be provided to healthcare workers in the intervention arm. Findings from previous CRP studies have been used to inform the training and guidance for the healthcare workers.
Face-to-face training will be provided on how the test could be used to inform their prescribing behaviour and a practical session on CRP testing. Content will include which patients should be offered CRP tests; CRP cut-off values; safety nets and caution in result interpretation (including danger signs from IMCI13 and IMAI14 guidelines and patients with co-morbidities). Healthcare workers will be advised that the CRP cut offs are guidelines and that antibiotics can be prescribed or withheld according to their clinical judgement. If the healthcare worker feels the patient requires referral to a higher level facility this should be done without delay and that the CRP tests should not be used in these cases. The training will be provided by the study team in the local language.
The CHCs and healthcare workers will be given a telephone number to contact should any queries arise during the study. Laminated posters and desk reminders with the CRP cut-off values will be given to the intervention sites.In addition to general information about rational antibiotic use contained in the patient leaflet, patients in the intervention arm will have an extra section explaining the role of CRP testing to guide antibiotic prescriptions.
Patient education - Patients with ARIs in all CHCs will be provided with an information leaflet regarding rational use of antibiotics in ARI and the implications of overuse of antibiotics for the development of AMR. An additional section for the intervention arm will explain the role of CRP testing to guide antibiotic prescriptions.
5. Clinical/laboratory/other procedures - CRP tests will be available for healthcare workers to use in ARI patients consulting at intervention CHCs. If patient agree to take the test, a finger prick blood sample will be taken by the CHC staff and placed on a semi-quantitative lateral flow CRP test-kit (Actim® CRP, Medix Biochemica, Finland). Results will be available within 5-10 minutes. Other than the finger prick sample for the CRP test no samples will be taken or stored. CRP test kits and other consumables will be re-stocked on a monthly basis provided and checked to confirm they are properly used for study the study purposes only.
6. Withdrawal of participants from the study - Healthcare workers will be free to refrain from using the tests and they are not obliged to follow the guidelines in their antibiotic prescribing. Healthcare workers will also be free to decline the interviews on the usability and acceptability of the tests. Patients' autonomy will be respected and they will be free to decline the CRP test.
7. Minimization of Error and Bias - To reduce bias within healthcare providers, cluster randomisation will be used so that the same doctors will not see patients in both the intervention and control groups. The study will be conducted for 1 year to allow for seasonal variation. To measure outcomes, electronic patient record data captured routinely in health station log books will be used. This information is a requirement for national health insurance reimbursements, and will be captured in the same way in each arm. Health-workers in both arms will receive data quality training at the start of the study period.
8. Serious adverse events monitoring - As the research poses no more than minimal risks to participants, a data and safety monitory board (DSMB) will not be required. Based on previous studies it's anticipated that no serious adverse events associated with the CRP tests and patients will not be followed up. However, data on admissions for ARI at hospitals serving this catchment population will be retrospectively requested. Health insurance numbers will be used to link with primary healthcare records, in order to identify any study patients who were subsequently hospitalised. This will be done at the end of the study.
1. Screening and Recruitment - A list of potential CHCs will be compiled by province-level officials, and those meeting eligibility criteria will be invited to take part. CHCs will be randomly allocated to intervention or routine care arms using a computer-generated random allocation procedure.
If baseline variability in antibiotic prescribing practices is identified from reviewing retrospective routine records, high and low prescription centres will be stratified.
In the intervention CHCs, patients with ARIs will be provided leaflets with information about CRP testing, antibiotics and AMR. Healthcare workers will then decide whether to use a CRP test as part of routine care of patients with ARI. Patients' autonomy will be respected and as with any medical procedure this test can be declined. In the control CHCs patients will be provided with an information leaflet regarding the need for rational use of antibiotics in ARIs but with no mention of CRP testing.
2. Clinical assessment - All patients will have a medical history taken and will be examined as per normal practice. In the control arm, local guidelines and WHO IMCI recommendations will guide treatment. In the intervention arm, doctors can choose to use CRP test results in addition to existing guidelines.
3. General training and education - Healthcare worker training - Before the study sites (CHCs) are randomized, an overview of the study will be presented to all local healthcare workers and provide education about the role of antibiotics, antimicrobial resistance and identification of clinical signs of severity as well as good clinical practice (GCP) for research.
Patient education - Educational materials will be developed for patients and care-givers regarding antibiotic use and AMR. These will be available to patients presenting with ARIs in both arms, with additional information regarding the CRP tests added to the intervention group leaflets.
4. Intervention - CRP test - The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.
Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.
As the purpose of the study is to establish whether antibiotic prescription rates can be reduced by using CRP POC test results, the healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs below are recommended in the absence of warning signs of severity:
CRP level \< 10 mg/L: no antibiotics are recommended CRP level from 10mg/L to 40 mg/L: antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level \> 40 mg/L: antibiotics are recommended. Based on the previous clinical trial of CRP testing in ARI in Vietnam in similar CHCs, it's anticipated approximately 75% of patients to have CRP levels below 10mg/L, 20% between 10-40mg/L and 5% above 40 mg/L6.
Healthcare worker training - Additional training will be provided to healthcare workers in the intervention arm. Findings from previous CRP studies have been used to inform the training and guidance for the healthcare workers.
Face-to-face training will be provided on how the test could be used to inform their prescribing behaviour and a practical session on CRP testing. Content will include which patients should be offered CRP tests; CRP cut-off values; safety nets and caution in result interpretation (including danger signs from IMCI13 and IMAI14 guidelines and patients with co-morbidities). Healthcare workers will be advised that the CRP cut offs are guidelines and that antibiotics can be prescribed or withheld according to their clinical judgement. If the healthcare worker feels the patient requires referral to a higher level facility this should be done without delay and that the CRP tests should not be used in these cases. The training will be provided by the study team in the local language.
The CHCs and healthcare workers will be given a telephone number to contact should any queries arise during the study. Laminated posters and desk reminders with the CRP cut-off values will be given to the intervention sites.In addition to general information about rational antibiotic use contained in the patient leaflet, patients in the intervention arm will have an extra section explaining the role of CRP testing to guide antibiotic prescriptions.
Patient education - Patients with ARIs in all CHCs will be provided with an information leaflet regarding rational use of antibiotics in ARI and the implications of overuse of antibiotics for the development of AMR. An additional section for the intervention arm will explain the role of CRP testing to guide antibiotic prescriptions.
5. Clinical/laboratory/other procedures - CRP tests will be available for healthcare workers to use in ARI patients consulting at intervention CHCs. If patient agree to take the test, a finger prick blood sample will be taken by the CHC staff and placed on a semi-quantitative lateral flow CRP test-kit (Actim® CRP, Medix Biochemica, Finland). Results will be available within 5-10 minutes. Other than the finger prick sample for the CRP test no samples will be taken or stored. CRP test kits and other consumables will be re-stocked on a monthly basis provided and checked to confirm they are properly used for study the study purposes only.
6. Withdrawal of participants from the study - Healthcare workers will be free to refrain from using the tests and they are not obliged to follow the guidelines in their antibiotic prescribing. Healthcare workers will also be free to decline the interviews on the usability and acceptability of the tests. Patients' autonomy will be respected and they will be free to decline the CRP test.
7. Minimization of Error and Bias - To reduce bias within healthcare providers, cluster randomisation will be used so that the same doctors will not see patients in both the intervention and control groups. The study will be conducted for 1 year to allow for seasonal variation. To measure outcomes, electronic patient record data captured routinely in health station log books will be used. This information is a requirement for national health insurance reimbursements, and will be captured in the same way in each arm. Health-workers in both arms will receive data quality training at the start of the study period.
8. Serious adverse events monitoring - As the research poses no more than minimal risks to participants, a data and safety monitory board (DSMB) will not be required. Based on previous studies it's anticipated that no serious adverse events associated with the CRP tests and patients will not be followed up. However, data on admissions for ARI at hospitals serving this catchment population will be retrospectively requested. Health insurance numbers will be used to link with primary healthcare records, in order to identify any study patients who were subsequently hospitalised. This will be done at the end of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Acute Respiratory Infection
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam (CHC details are described in the Location section below). Prior to introduction of the tests, an educational session will be provided for local healthcare workers in both intervention and control arms about the role of antibiotics and AMR. After randomization, further training will be provided for healthcare workers in the intervention CHCs as to the use of CRP testing to guide antibiotic prescribing decisions. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI (detailed in section 5.4). Educational materials will also be developed for patients and care-givers regarding the value of CRP testing.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.
Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.
The healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs will be recommended below in the absence of warning signs of severity:
CRP level \< 10 mg/L: no antibiotics are recommended CRP level from 10 mg/L to 40 mg/L: antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level \> 40 mg/L: antibiotics are recommended.
Group Type
EXPERIMENTAL
ACTIM CRP Rapid Test (Medix, Biochemica)
Intervention Type
DIAGNOSTIC_TEST
The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
Control
Working as routine
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACTIM CRP Rapid Test (Medix, Biochemica)
The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged from 1 to under 65 years old
* First consultation with an acute respiratory infection diagnosed by the healthcare worker with at least 1 focal sign or symptom\*
* Symptoms lasting less than 7 days \* Focal signs and symptoms: (1) cough, (2) rhinitis (sneezing, nasal congestion, or runny nose), (3) pharyngitis (sore throat), (4) shortness of breath, (5) wheezing, (6) chest pain, or (7) auscultation abnormalities.
* First consultation with an acute respiratory infection diagnosed by the healthcare worker with at least 1 focal sign or symptom\*
* Symptoms lasting less than 7 days \* Focal signs and symptoms: (1) cough, (2) rhinitis (sneezing, nasal congestion, or runny nose), (3) pharyngitis (sore throat), (4) shortness of breath, (5) wheezing, (6) chest pain, or (7) auscultation abnormalities.
Exclusion Criteria
* Patients requiring referral to a higher level facility based on the healthcare worker's clinical assessment
* immunosuppressed patients (known HIV, long term steroid use)
* those with a suspicion of tuberculosis or a non-respiratory tract illness
* immunosuppressed patients (known HIV, long term steroid use)
* those with a suspicion of tuberculosis or a non-respiratory tract illness
Minimum Eligible Age
1 Year
Maximum Eligible Age
64 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Hospital for Tropical Diseases, Hanoi, Vietnam
OTHER_GOV
Sponsor Role
collaborator
Oxford University Clinical Research Unit, Vietnam
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Hospital for Tropical Diseases
Hanoi, , Vietnam
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Vietnam
References
Explore related publications, articles, or registry entries linked to this study.
Kaya Z, Kucukcongar A, Vuralli D, Emeksiz HC, Gursel T. Leukocyte populations and C-reactive protein as predictors of bacterial infections in febrile outpatient children. Turk J Haematol. 2014 Mar;31(1):49-55. doi: 10.4274/Tjh.2013.0057. Epub 2014 Mar 5.
Reference Type
BACKGROUND
Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005 Feb 12-18;365(9459):579-87. doi: 10.1016/S0140-6736(05)17907-0.
Reference Type
BACKGROUND
Shallcross LJ, Davies DS. Antibiotic overuse: a key driver of antimicrobial resistance. Br J Gen Pract. 2014 Dec;64(629):604-5. doi: 10.3399/bjgp14X682561. No abstract available.
Reference Type
BACKGROUND
Greer RC, Intralawan D, Mukaka M, Wannapinij P, Day NPJ, Nedsuwan S, Lubell Y. Retrospective review of the management of acute infections and the indications for antibiotic prescription in primary care in northern Thailand. BMJ Open. 2018 Jul 30;8(7):e022250. doi: 10.1136/bmjopen-2018-022250.
Reference Type
BACKGROUND
Aabenhus R, Jensen JU, Jorgensen KJ, Hrobjartsson A, Bjerrum L. Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. Cochrane Database Syst Rev. 2014 Nov 6;(11):CD010130. doi: 10.1002/14651858.CD010130.pub2.
Reference Type
BACKGROUND
Do NT, Ta NT, Tran NT, Than HM, Vu BT, Hoang LB, van Doorn HR, Vu DT, Cals JW, Chandna A, Lubell Y, Nadjm B, Thwaites G, Wolbers M, Nguyen KV, Wertheim HF. Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary health care: a randomised controlled trial. Lancet Glob Health. 2016 Sep;4(9):e633-41. doi: 10.1016/S2214-109X(16)30142-5. Epub 2016 Aug 3.
Reference Type
BACKGROUND
Althaus T, Greer RC, Swe MMM, Cohen J, Tun NN, Heaton J, Nedsuwan S, Intralawan D, Sumpradit N, Dittrich S, Doran Z, Waithira N, Thu HM, Win H, Thaipadungpanit J, Srilohasin P, Mukaka M, Smit PW, Charoenboon EN, Haenssgen MJ, Wangrangsimakul T, Blacksell S, Limmathurotsakul D, Day N, Smithuis F, Lubell Y. Effect of point-of-care C-reactive protein testing on antibiotic prescription in febrile patients attending primary care in Thailand and Myanmar: an open-label, randomised, controlled trial. Lancet Glob Health. 2019 Jan;7(1):e119-e131. doi: 10.1016/S2214-109X(18)30444-3.
Reference Type
BACKGROUND
Evrard B, Roszyk L, Fattal S, Dastugue B, Sapin V. [Evaluation of rapid, semi-quantitative assay of C-reactive protein in whole blood, Actim CRP]. Ann Biol Clin (Paris). 2005 Sep-Oct;63(5):525-9. French.
Reference Type
BACKGROUND
Brouwer N, van Pelt J. Validation and evaluation of eight commercially available point of care CRP methods. Clin Chim Acta. 2015 Jan 15;439:195-201. doi: 10.1016/j.cca.2014.10.028. Epub 2014 Oct 31.
Reference Type
BACKGROUND
Senn N, Rarau P, Salib M, Manong D, Siba P, Rogerson S, Mueller I, Genton B. Use of antibiotics within the IMCI guidelines in outpatient settings in Papua New Guinean children: an observational and effectiveness study. PLoS One. 2014 Mar 13;9(3):e90990. doi: 10.1371/journal.pone.0090990. eCollection 2014.
Reference Type
BACKGROUND
WHO. Integrated Management of Childhood Illness. Geneva, Switzerland; 2014
Reference Type
BACKGROUND
The World Health Organization. Integrated management of adolescent and adult illness: interim guidelines for first-level facility health workers at health centre and district outpatient clinic: acute care. 2009; Rev 3
Reference Type
BACKGROUND
Sim J, Dawson A. Informed consent and cluster-randomized trials. Am J Public Health. 2012 Mar;102(3):480-5. doi: 10.2105/AJPH.2011.300389. Epub 2012 Jan 19.
Reference Type
BACKGROUND
Lubell Y, Blacksell SD, Dunachie S, Tanganuchitcharnchai A, Althaus T, Watthanaworawit W, Paris DH, Mayxay M, Peto TJ, Dondorp AM, White NJ, Day NP, Nosten F, Newton PN, Turner P. Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in Southeast Asia. BMC Infect Dis. 2015 Nov 11;15:511. doi: 10.1186/s12879-015-1272-6.
Reference Type
BACKGROUND
Do NTT, Vu TVD, Greer RC, Dittrich S, Vandendorpe M, Pham NT, Ta DN, Cao HT, Khuong TV, Le TBT, Duong TH, Nguyen TH, Cai NTH, Nguyen TQT, Trinh ST, van Doorn HR, Lubell Y, Lewycka S. Implementation of point-of-care testing of C-reactive protein concentrations to improve antibiotic targeting in respiratory illness in Vietnamese primary care: a pragmatic cluster-randomised controlled trial. Lancet Infect Dis. 2023 Sep;23(9):1085-1094. doi: 10.1016/S1473-3099(23)00125-1. Epub 2023 May 22.
Reference Type
DERIVED
Thi Thuy Do N, Greer RC, Lubell Y, Dittrich S, Vandendorpe M, Nguyen VA, Ngoc Thach P, Thi Dieu Ngan T, Van Kinh N, Hung Thai C, Dung LTK, Nguyen Thi Cam T, Nguyen TH, Nadjm B, van Doorn HR, Lewycka S. Implementation of C-reactive protein point of care testing to improve antibiotic targeting in respiratory illness in Vietnamese primary care (ICAT): a study protocol for a cluster randomised controlled trial. BMJ Open. 2020 Dec 23;10(12):e040977. doi: 10.1136/bmjopen-2020-040977.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
http://www.wpro.who.int/health_services/service_delivery_profile_vietnam.pdf
Ministry of Health. Vietnam health service delivery profile
https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf
World Health Organisation. International ethical guidelines for health-related research involving humans.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
31HN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Improving Antibiotic Use in Acute Care Treatment
NCT00144040
COMPLETED
NA
Effect of CRP and SAA Point-of-care Testing on Antibiotic Prescribing for Acute Respiratory-tract Infections
NCT06568432
RECRUITING
NA
Advancing Access to Diagnostic Innovation Essential for UHC and AMR Prevention
NCT04081051
COMPLETED
NA
CRP and Patient Information Leaflets to Optimise Antibiotic Treatments for Adults With Respiratory Tract Infections in Primary Care in Kyrgyzstan
NCT07261969
RECRUITING
NA
Antibiotic Stewardship in AECOPD Through CRP-Guided Management
NCT05286918
NOT_YET_RECRUITING
NA
Research Title: Efficacy and Safety of Point- Of-care Procalcitonin Test to Reduce Antibiotic Exposure in VAP
NCT03982667
COMPLETED
NA
Time to Appropriate Antibiotic Between Using Microarray Assay and Mass Spectrometry Technique
NCT03583762
UNKNOWN
NA
Effectiveness of Improving Diagnostic and Communication Skills on Antibiotic Prescribing Appropriateness in Acute Cough
NCT03931577
UNKNOWN
NA
Optimising Diagnosis and Antibiotic Prescribing for Acutely Ill Children in Primary Care
NCT02024282
COMPLETED
NA
A Rapid Test for Acute Respiratory Illness
NCT03192072
COMPLETED
Role of Multiplex PCR in CAP
NCT06097117
UNKNOWN
DiagNostic Study of Low-dose CT and multipleX PCR on Antibiotic Treatment and Outcome of Community-Acquired Pneumonia
NCT03360851
TERMINATED
NA
Differential Diagnostics of Etiology of Acute Infections
NCT03161951
COMPLETED
Clinical Characteristics And Outcome Of COVID-19 Infection In Patients With Chronic Respiratory Diseases.
NCT05054127
UNKNOWN
Fast Identification of Pathogen in the Setting of Pneumonia Using Multiplex PCR
NCT01858974
COMPLETED
ADEQUATE Advanced Diagnostics for Enhanced Quality of Antibiotic Prescription
NCT04547556
TERMINATED
NA
Improved Use of Antibiotic Guidelines in Hospital Environment
NCT00512772
COMPLETED
Assessing Performance of the Testing Done Simple Covid 19 Antigen Test
NCT05610449
COMPLETED
The Predictive Value of Molecular Diagnostic Techniques in the Antimicrobial- Resistance Phenotypes of Pathogens
NCT07035535
ENROLLING_BY_INVITATION
Point-of-Care Multiplex for Adult Patients With Severe Community-acquired Pneumonia
NCT04835818
UNKNOWN
NA
HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array
NCT05952648
RECRUITING
NA
Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application
NCT01922024
COMPLETED
Early Identification and Severity Prediction of Acute Respiratory Infectious Disease
NCT04955756
UNKNOWN
NA
Impact on the Use of Antibiotics of a Multimodal Algorithm for the Diagnosis and Management of Acute Community-acquired Pneumonia in the Emergency Room
NCT05657275
COMPLETED
NA
Point of Care Respiratory Pathogen Testing for Antibiotic Stewardship in Primary Care
NCT06765135
ENROLLING_BY_INVITATION
NA